The Consortium
The MitoTarget consortium has extensive expertise in neurodegenerative diseases
The information provided in this web site is intended to educate the reader about certain medical conditions and certain possible treatments. It is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. If you believe you, suffer from the conditions described herein, please see your health care provider. Do not attempt to treat yourself or anyone else without proper medical supervision.
Read the Full Disclaimer
Institutions & Investors
Latest News
Disappointing results of olesoxime clinical trial announced
13 December 2011 Results from a recent clinical trial into motor neurone disease (MND), involving people with MND in England, have been announced and show the trial drug to be ineffective a
Trophos announces results of phase 3 study of olesoxime in ALS
MARSEILLE, FRANCE – December 13 2011. Trophos SA announces today the results from the phase 3 study of Trophos’ lead compound, olesoxime, in 512 patients with ALS.
Trophos announces final patient completion of pivotal phase three efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease)
Top-line results expected fourth quarter 2011 Marseille, France, September 22, 2011 - Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discov
